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Abstract
Background: Early rising asexual parasitaemia (ERAP), initially defined as ‘an increase in the parasite count over the
baseline pre-treatment level during the first 24 h of treatment’ of falciparum malaria with artemisinin derivatives is
well documented, but there is no characterization of its risk factors, kinetics, molecular features or relationship to
late-appearing anaemia (LAA) in acute falciparum malaria in African children following oral artemisinin-based
combination therapies (ACTs).
Methods: ERAP was defined as ≥5% increase in pre-treatment parasitaemia within 8 h of initiating treatment.
Parasitaemia was quantified pre-treatment and 1–2 hourly for 8 h, and less frequently thereafter for 6 weeks
following randomized treatment of acutely malarious children with artesunate-amodiaquine, artemether-
lumefantrine or dihydroartemisinin-piperaquine. Risk factors were determined by stepwise multiple logistic
regression model. Kinetics of release into and of elimination of asexual parasites and DNA clones from peripheral
blood were evaluated by method of residuals and non-compartment model, respectively. Parasite population
changes were evaluated morphologically and by molecular genotyping.
Results: ERAP occurred in 205 of 416 children. A parasitaemia <100,000/μL and parasitaemia 1 day post-treatment
initiation were independent predictors of ERAP. In children with ERAP: mean and peak time of increase in
parasitaemia were 105.6% (95% CI 81–130.1) and 2.5 h (95% CI 2.2–2.7), respectively. Mean lag time, half-time and
rate constant of release were 0.2 h (95% CI 0.2–0.3), 1 h (95% CI 0.9–1.1), and 0.9 h−1 (95% CI 0.8–1), respectively.
Schizonts and young gametocytes were seen only in peripheral blood of few children with ERAP. In age-, gender-,
baseline parasitaemia- and treatment-matched children with and without ERAP, parasite DNA clearance time and
area under curve of number of DNA clones versus time were significantly higher in children with ERAP indicating
peripheral retention of released parasites followed by elimination. DNA clone elimination was monoexponential.
Conclusion: ERAP is common, occurs rapidly as first order process and may be due to mobilization of parasites
from deep tissue following a first dose of ACTs of acute childhood falciparum malaria.
Trials registration: Pan African Clinical Trial Registry PACTR201508001188143, 3 July 2015; PACTR201510001189370,
3 July 2015; PACTR201508001191898, 7 July 2015 and PACTR201508001193368, 8 July 2015.
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Background
Early rising asexual parasitaemia (ERAP), originally de-
scribed as an increase in parasite count over the baseline
pre-treatment level occurring within 24 h following treat-
ment of falciparum malaria with artemisinin-like drugs
[1], may occur in 25–45% of malarious patients following
artemisinin-based combination treatments (ACTs) [1–3].
Although prognosis is favourable in malarious Thai and
Nigerian patients with ERAP [1–3], the factors contribut-
ing to ERAP, and the additional burden posed by it are lit-
tle evaluated. Given that early increases in parasitaemia
may be accompanied by changes in asexual and sexual
parasite populations following ACTs and may be relatively
short-lasting by morphological assessment [3], evaluation
of ERAP by polymerase chain reaction (PCR) genotyping
and kinetics of parasite population changes are urgently
needed as they may provide insight into the possible
cause(s) and consequences of ERAP and the possible
mechanisms of ACTs-related ERAP.
Of the estimated 214 million clinical episodes of malaria
reported annually, 188 million clinical episodes occur in
Africa mainly in children [4]. In Nigeria, an estimated over
37 million clinical episodes of falciparum malaria are re-
ported annually [5]. Although acute falciparum infections
are associated with anaemia in 25–80% of African children
at presentation [6–8], it is increasingly apparent additional
burden of anaemia may be imposed by a late-appearing
anaemia (LAA) following successful ACTs of apparently
uncomplicated infections [7, 9, 10]. The extent of this
additional burden and its relationship to ERAP, if any,
following ACTs in African children remain unknown.
In order to determine the factors contributing to ERAP,
its release and disposition kinetics, its consequences and
other additional burden it may pose, and the association be-
tween ERAP and LAA, larger number of well-characterized
patients and comparison with patients without ERAP are
needed. For these reasons, we added asexual parasite
kinetic analyses and molecular genotyping to the clinical
and parasitological characterization of children with ERAP
following a first dose of ACTs of apparently uncomplicated
Plasmodium falciparum malaria in children. The aims of
the study were to determine in malarious children with
ERAP: its frequency and the factors contributing to it; its
consequences; the kinetics of release into and of the dispos-
ition of asexual stage parasites from peripheral blood dur-
ing ERAP; asexual stage and gametocyte stage population
changes; asexual stage genotyping during ERAP; and the re-
lationship, if any, between ERAP and LAA following ACTs.
Methods
Study location
The study was conducted between January 2008 and
December 2015 in Ibadan, an endemic area of malaria
in southwestern Nigeria. It was part of a larger and
longer study of the efficacies of artemisinin-based com-
bination treatments - artesunate-amodiaquine (AA),
artemether-lumefantrine (AL) and dihydroartemisinin-
piperaquine (DHP). Details of the study have been
described elsewhere [7]. The study protocol was ap-
proved by The Ethics Committee of The Ministry of
Health, Ibadan and by National Health Research
Ethics Committee, Abuja, Nigeria [Pan African Clin-




Inclusion and exclusion criteria
Patients were enrolled in the study if they met the
following criteria: age 6 months–15 years, symptoms
compatible with acute uncomplicated malaria with
Plasmodium falciparum mono-infections ≥2000 μL−1 of
blood, no history of antimalarial drug ingestion in the
2 weeks prior to enrolment, absence of severe malaria
[11–13], written informed consent given by parents or
guardians and ability to comply with a 42-day follow-
up period. Patients with uncomplicated hyperparasitae-
mia (parasitaemia >250,000 μL−1) were not excluded
from the study [13]. Patients with severe malnutrition
(i. e. weight for age < 60% and bilateral oedema) and
those with sickle cell anaemia were excluded from the
study. Patient selection and enrolment were done by a
physician who did not participate in patient evaluation
once treatment began [7].
Drug treatment
Patients were randomised to and received artesunate-
amodiaquine, artemether-lumefantrine or dihydroarte
misinin-piperaquine orally as previously described [7]
(Table 1). Each randomization envelope was opened at
the time of treatment by the attending nurse or physician.
Each tablet of artemether-lumefantrine (Coartem®,
Novatis, Basel, Switzerland) contains 20 mg of arte-
mether and 120 mg of lumefantrine. Each tablet of
dihydroartemisinin-piperaquine (Duo-cotecxin®, Zhejiang
Holley Nanhu, China) contains 40 mg of dihydroartemisi-
nin and 320 mg of piperaquine. The formulations of
artesunate-amodiaquine (Coarsucam®, Sanofi Aventis,
France) are 25 mg/67.5 mg, 50 mg/135 mg, 100 mg/
270 mg of fixed dose combination. All drugs were given
within 3 min of obtaining enrolment (pre-treatment, base-
line) blood slides for quantification of parasitaemia.
Patient evaluation
Clinical evaluation and monitoring for adverse events
were done at the following times: before treatment (day
0; that is, the day treatment began) and at 1, 2, 3, 7, 14,
21, 28, 35 and 42 days after start of treatment. Clinical
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evaluation consisted of physical examination and meas-
urement of body temperature, heart and respiratory
rates. Side effects were defined as symptoms and signs
that first occurred or became worse after treatment
started and were checked for at every visit. Any new
events occurring during treatment were also considered
as side effects.
Parasitological evaluation
Thick and thin blood films prepared from a finger prick
were obtained at the following times: before treatment
(0 h), and at 1, 2, 4, 6, 8, 24, 48, 72, 96, 120, 144, 168, 336,
504 and 672 h and then on days 35 and 42 after initiation
of treatment. Blood slides were stained with Giemsa and
examined by light microscopy under oil immersion object-
ive lens at 1000 × magnification by two assessors who did
not know the drug regimen of the patients. A senior
member of the study team reviewed the slides if there was
any disagreement between the two microscopists. In
addition, the slide of every fourth child enrolled in the
study was reviewed by the senior member.
Parasitaemias, asexual or sexual, in thick films were esti-
mated by counting asexual and sexual parasites relative to
500 leukocytes, or 500 asexual or sexual forms whichever
occurred first. From this figure, the parasite density was
calculated assuming a leukocyte count of 6,000 μL−1 of
blood [14–16]. A slide was considered parasite negative if
no asexual or sexual parasite was detected after examin-
ation of 200 microscope fields.
Definition of ERAP
ERAP was defined as ≥5% increase in pre-treatment
asexual parasitaemia occurring within 8 h of initiating
ACTs.
Staging of asexual and sexual parasites development in
peripheral blood
Stages of asexual parasite development in peripheral
blood were estimated as follows: R1: width of cytoplasm/
diameter of nucleus <0.5, that is, ring form aged 0- < 6 h.
R2: width of cytoplasm/diameter of nucleus >0.5- < 1,
that is, ring form aged 6- < 18 h. R3: width of cytoplasm/
diameter of nucleus >1, that is, ring form aged 18–24 h.
Late trophozoite, that is aged >24–40 h and containing 2
nuclei. Schizonts, that is, >40 h and containing at least 3
nuclei [17]. Gametocytes were sexed according to the
following morphological criteria: males (microgameto-
cytes) are smaller than females (macrogametocytes), the
nucleus is larger in males than in females, the end of the
cells are rounder in males and pointed in females, with
Giemsa the cytoplasm stains purple in males and deep
blue in females, and the granules of malaria pigment are
centrally located in females and more widely spread
scattered in males [18, 19]. Gametocytes were classified
morphologically as male or female if at least three of the
five criteria stated above were present. Gametocytes
were considered immature or young when they are
Stage I–III, or mature when they are Stage IV–V [20].
Gametocytes were classified as stage II if they were
elongated in the erythrocytes or had a D-shape and
were distinguished from late trophozoite with 2 nuclei.
Gametocytes sex ratio, the proportion of gametocytes
that is male [21, 22], was not evaluated.
PCR genotyping
PCR genotyping was done as described previously
[23, 24]. P. falciparum loci that exhibited repeated num-
bers of polymorphisms to distinguish between different
parasite populations were used for characterization of
population structure. Block 2 of merozoite surface
protein-1 (MSP-1), block 3 of MSP-2, and region II of
glutamine-rich protein (GLURP) were amplified by nested
polymerase chain reaction (PCR) using primers and amp-
lification conditions described previously [23, 24]. Ten
microlitres of the PCR products was resolved by electro-
phoresis on a 2% agarose gel and sized against 1000-
basepair (bp) molecular weight marker (New England
Biolabs, Beverly, MA). Primers sequences and PCR condi-
tions for the nested PCR strategy were as previously
described [23, 24]. Each P. falciparum infection was char-
acterized on the basis of the fragment size of the PCR
products for each locus and determining size of the alleles
of MSP-1, MSP-2 and GLURP. Infections were defined as
polyclonal if parasites from the same patient showed more
than one allele on one or more genes. If an isolate had
one allele at each of the 3 loci, the clone was taken to be
one. Extracted parasite DNA was not quantified but inten-
sity of parasite DNA band and time of maximal intensity
was noted on electrophoresis in each patient. Because




5–14 kg received 1 tablet
15–24 kg received 2 tablets
25–34 kg received 3 tablets
>34 kg received 4 tablets, at presentation (0 h), 8 h later and at 24,
36, 48 and 60 h after the first dose.
Artesunate-amodiaquine
Patients weighing:
≥4.5- < 9 kg received 1 tablet of 25 mg/67.5 mg formulation
≥9- < 18 kg received 1 tablet of 50 mg/135 mg formulation
≥18- < 24 kg received 1 tablet of 100 mg/270 mg formulation
24–36 kg received 1.5 tablet of 100 mg/270 mg formulation
>36 kg received 2 tablets of 100/270 mg formulation, daily for 3 days.
Dihydroartemisinin-piperaquine
Patients weighing:
≥4.5 - <10 kg received ¾ of 1 tablet
10 - <16 kg, received 1.5 tablet
16 - <24 kg, received 2 tablets
24 - <34 or received 2.5 tablets
34 - <50 kg received 3 tablets, daily for 3 days.
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qPCR was not performed, internal controls like human
housekeeping genes were not used. However, DNA con-
centration in different time point samples were quantified
using a NanoDrop 2000c. Equal volumes of DNA were
used in a 25 μL final volume of PCR reaction. Parasite
DNA clearance time was defined as time from commence-
ment of treatment until there was no detectable parasite
DNA by genotyping.
Haematological evaluation
Capillary blood collected before treatment and during
follow-up was used to measure haematocrit using a
microhaematocrit tube and microcentrifuge (Hawksley,
Lancing, UK). Anaemia was defined as a haematocrit <
30% [6, 25]. Late-appearing anaemia (LAA)] was de-
fined as anaemia occurring after 2 weeks of starting
treatment [7]. A diagnosis of late-appearing anaemia
was made if the following criteria were met following
initiation of artemisinin-based combination treatments:
clearance of parasitaemia and other symptoms within
1 week, haematocrit ≥ 30% at 1 and/or 2 weeks, a fall in
haematocrit to < 30% occurring at 3–6 weeks, absence
of concomitant illness at 1–6 weeks, and absence of
asexual parasitaemia by both microscopy and PCR at
3–6 weeks [7]. Anaemia recovery time (in anaemic pa-
tients at presentation) was defined as time elapsing
from start of drug administration to attainment of a
haematocrit value ≥ 30% [26, 27]. Fall in haematocrit
(FIH) per 1000 asexual parasites cleared from peripheral
blood following treatment [FIH/1000 asexual parasites
cpb] was defined as relative difference in haematocrit at
baseline (pre-treatment) and the first 1 or 2 days after
treatment began as numerator, and the corresponding
relative difference in parasitaemia as the denominator, and
expressing it per 1000 asexual parasites cleared from per-
ipheral blood [28].
Evaluation of response to treatment
Response to drug treatment was assessed using a modified
version of the World Health Organization in vivo clinical
classification criteria [29]. The clinical classification system
consisted of the following categories of response: adequate
clinical and parasitological response (ACPR), late parasito-
logical failure (LPF), late clinical failure (LCF), and early
treatment failure (ETF). The primary outcomes were the 42-
day uncorrected and PCR-corrected efficacy. The secondary
outcomes were the fever clearance time, parasite clearance
time and recovery from malaria-associated anaemia.
The cure rates on days 28 and 42 were adjusted on the
basis of the PCR (polymerase chain reaction) genotyping
results of paired samples of patients with recurrent parasit-
aemia after day 7 of starting treatment as previously de-
scribed [23]. Fever clearance time (FCT) in patients with
presenting body temperature ≥ 37.5 °C was defined as time
elapsing from start of treatment until temperature fell
below 37.5 °C and remained so for at least 48 h. Parasite
clearance time (PCT) was defined as time elapsing from
start of drug administration until there was no patent para-
sitaemia for at least 72 h. Asexual parasite reduction ratio
(PRR) [30] was defined as the ratio of day 0/day 2 para-
sitaemia (and for convenience, referred to as PRRD2).
Asexual parasite reduction ratio on day 1 (PRRD1) was
defined as the ratio of day 0/day 1 parasitaemia.
Kinetics of release of asexual parasites into and of their
disposition from peripheral blood in children with ERAP,
and of the disposition of asexual parasites in children
without ERAP
In order to characterize the release of asexual parasites
into peripheral blood from ‘deep tissue’, a graphic pro-
cedure similar to that for testing whether drug absorp-
tion is a first–order process, and if so, to determine the
absorption half-life - the method of residuals, was
adapted [31]. Asexual parasites in deep tissue was as-
sumed to be the administered ‘drug’ and the rate of in-
crease and decrease in peripheral blood asexual
parasites, the ‘drug’ absorbed into circulation as fol-
lows: in each patient, on a semi-log plot of parasite
density (concentration) versus time, the linear portion
of the decline phase was back extrapolated. The con-
centration along the extrapolated line was denoted as
C
←
. The observed parasite concentration during the ris-
ing phase, denoted as C, was subtracted from the corre-
sponding extrapolated value at each time point, that is,
C
←





against time on the same semi-logarithmic graph paper.
Release half-time (the equivalent of absorption half-time)
was determined from this plot. Rate constant for release
(Kerap) [the equivalent of absorption rate constant] was
calculated as 0.693/t½erap. Lag time for release (the equiva-
lent of time between drug administration and onset of





This time was assumed to be the interval between time of
administration of first dose of ACTs and the onset of re-
lease of asexual parasites from deep tissue into peripheral
blood (see reference [31] for the underlying basis of the
method of residuals and its equations). Areas under curve
(AUC) of the plot of parasitaemia versus time, and of the
plot of clone number versus time were estimated by trap-
ezoidal method [31]. Kinetics of elimination of parasit-
aemia were evaluated as previously described [32, 33].
Statistical analysis
Data were analyzed using version 6 of Epi-Info software
[34] and the statistical program SPSS for Windows ver-
sion 20.0. [35]. Variables considered in the analysis were
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related to the densities of P. falciparum asexual and sexual
forms. Proportions were compared by calculating χ2 using
Yates’ correction, Fisher’s exact or Mantel Haenszel tests.
Normally distributed, continuous data were compared by
Student’s t test and analysis of variance (ANOVA). Data
not conforming to a normal distribution were compared
by the Mann–Whitney U tests and the Kruskal Wallis
tests. The relationship between two variables that are con-
tinuous and normally distributed, and those that are
discrete and not normally distributed were evaluated by
Pearson correlation coefficient and Spearman’s rank cor-
relation coefficient, respectively. A stepwise multiple logis-
tic regression model was used to test the association
between early rising asexual parasitaemia and factors that
were significant at univariate analysis: parasitaemia
<100,000/uL, parasitaemia 1 day after treatment began,
and parasite reduction ratio <104 1 day after treatment
began. Because the study was conducted over a period of
7 years, time in years since the commencement of the
study was included as a dichotomous covariate in the
model for early rising asexual parasitaemia. P values of
<0.05 were taken to indicate significant differences. Data
were double entered serially using patients’ codes and
were only analyzed at the end of the study.
Results
Characteristics of patients enrolled in the study and
treatment outcomes
The characteristics of children enrolled in the study are
shown in Table 2. These characteristics are similar in
children with and without ERAP. However, children with
ERAP had significantly lower enrolment geometric mean
parasitaemia [52,392 μL−1 (range 2,220–536,912, n =
205) versus 61,933 μL−1 (range 1,800–1,096,636, n =
211), respectively, P = 0.01] and proportion with a para-
sitaemia >100,000 μL−1 (19.6% versus 40.3%, P < 0.0001).
Frequency of early rising asexual parasitaemia
Two hundred and five of 416 children (49%) had ERAP
and it occurred with similar frequencies in those treated
with artesunate-amodiaquine, artemether-lumefantrine
or dihydroartemisinin-piperaquine [107 of 240 (45%)
versus 64 of 120 (53%) versus 34 of 56 (61%), respect-
ively, P = 0.054]. ERAP was significantly more frequent
in the first 4 h following initiation of treatment com-
pared to > 4 h after start of treatment (187 of 416 versus
18 of 416 (P < 0.0001) (Fig. 1).
Factors contributing to early rising asexual parasitaemia
Factors at presentation associated with ERAP following
ACTs are presented in Table 3. In a univariate analysis,
an enrolment parasitaemia <100,000 μL−1, parasite posi-
tivity on day 1 and parasite reduction ratio <104 one day
after treatment began were related to ERAP. Gender,
age, duration of illness, temperature at presentation, fever
1 day after treatment began, anaemia at presentation and
1 day after treatment began, FIH/1000 asexual parasites cpb,
fever clearance time, parasite reduction ratio 2 days after
treatment began, and year and season of enrolment were not
related to ERAP. In a multivariate analysis, an enrolment
parasitaemia <100,000 μL−1 and parasite positivity 1 day after
treatment began were independent predictors of ERAP.
Time-course of parasitaemia in patients with or without
early rising asexual parasitaemia
The time-course of parasitaemia in children with or with-
out ERAP is shown in Fig. 2.
(a). Increase in pre-treatment parasitaemia after first dose
of ACTs
Table 2 Clinical, parasitological and other parameters at
enrolment in children with or without early rising asexual
parasitaemia following artemisinin-based combination treatments









116/89 [43] 117/94 [45] 233/183 [44] 0.89
Age (year)
Mean 7.8 7.5 7.6 0.44
95% CI 7.3–8.2 7.1–8 7.3–8
No. < 5 years 36 48 84 0.23
Duration of illness (day)
Mean 2.8 2.8 2.8 0.52
95% CI 2.6–2.9 2.6–3 2.7–2.9
Temperature (°C)
Mean 38.3 38.1 38.2 0.51
95% CI 38.1–38.5 37.9–38.3 38.1–32.7
No. ≥ 37.5 °C 154 141 295 0.06
No. ≥ 40 °C 15 15 30 0.94
Haematocrit (%)
Mean 32.1 32.4 32.3 0.43
95% CI 31.5–32.7 31.8–33 31.8–32.7
No. <30% 49 47 96 0.78
Parasitaemia (μL−1)









40 85 125 <0.0001
No. ≥ 250,000
μL−1
12 24 36 0.045
CI confidence interval
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Overall, mean maximum increase in parasitaemia
over baseline (pre-treatment) was 96% (95% CI 73.4–
118.6, n = 226) in all children. In children with ERAP,
overall, mean maximum increase in pre-treatment
parasitaemia was 105.6% (95% CI 81–130.1, n = 205),
and it was similar with all 3 treatments [92.5%
(95% CI 62.2–122.4, n = 107) versus 125.5%
(95% CI 69.9–181.2, n = 64) versus 109.3% (95% CI
56.8–161.1, n = 34) in artesunate-amodiaquine,
artemether-lumefantrine and dihydroartemisinin-
piperaquine treatment groups, respectively, P = 0.5].
In children without ERAP mean maximum increase
in parasitaemia was 2.5% (95% CI 1.9–3.1, n = 21). At
presentation, geometric mean parasitaemia was
significantly higher in children without ERAP
compared with those with ERAP [61,933 μL−1
(range 1,800–1,096,636) versus 52,392 μL−1 (range
2,220–536,912), P = 0.01]. However at other times
following the first dose of ACTs, geometric mean
parasitaemia was significantly higher in children with
ERAP compared with those without [geometric mean
70,313 μL−1 (range 2,136 – 763,500) versus 37,425 μL
−1 (range 177 – 473,059), P < 0.0001; geometric mean
61,965 μL−1 (range 2,976 – 838,500) versus 29,719 μL
−1 (range 60 – 358,800), P < 0.0001; geometric mean
52,778 μL−1 (range 210 – 785,610) versus 20,873 μL−1
(range 30 – 326,400), P < 0.0001; geometric mean
33,660 μL−1 (range 980 – 53,100) versus 8,834 μL−1
(60 – 141,556), P < 0.0001; geometric mean
28,360 μL−1 (range 36 – 616,119) versus 11,406 μL−1
(range 23 – 367,647), P = 0.002 at 1, 2, 4, 6 and 8 h,
respectively].
(b).Time to peak parasitaemia after first dose of ACTs
Overall, time to peak parasitaemia in all children
after the first dose was 1.3 h (95% CI 1.1–1.5,
n = 226). In children with ERAP, mean peak asexual
parasitaemia occurred at 2.5 h (95% CI 2.2–2.7,
n = 205), and it was similar with all 3 treatments
[2.3 h (95% CI 2–2.7, n = 107) versus 2.5 h (95%
CI 2–3, n = 64) versus 2.8 h (95% CI 2.2–3.5,
n = 34) in artesunate-amodiaquine, artemether-
lumefantrine and dihydroartemisinin-piperaquine
treatment groups, respectively, P = 0.39]. In
children without ERAP, time to peak parasitaemia
occurred at 0.2 h (95% CI 0.1–0.3, n = 21), and
it was significantly lower than in those with
ERAP (P < 0.0001).
(c). Parasite and fever clearance
Overall, mean parasite clearance time was 29 h
(95% CI 27.2–30.8, n = 416). Parasite clearance was
significantly faster in children without compared to
those with ERAP [27.9 h (95% CI 26.5–29.3, n = 211)
versus 32.1 h (95% CI 30.2–33.9, n = 205),
respectively, P < 0.0001]. In those with ERAP,
parasite clearance was significantly faster in
artesunate-amodiaquine-treated children
compared with artemether-lumefantrine- or
dihydroartemisinin-piperaquine-treated children
[28.1 h (95% CI 26.7–29.5, n = 240) versus 30.6 h
(95% CI 28.4–32.8, n = 120) versus 36.4 h (95% CI
32.5–40.3, n = 56), respectively, P = 0.04]. In those
without ERAP, parasite clearance was significantly
slower in dihydroartemisinin-piperaquine-treated
children compared with artesunate-amodiaquine-
or artemether-lumefantrine-treated children [34.6 h
(95% CI 28.6–41.2, n = 22) versus 27.4 h (95% CI
25.7–29.2, n = 133) versus 26.1 h (95% CI 24.3–28,
n = 56), respectively, P = 0.002]. Overall, PCR cor-
rected ACPR on days 28–42 was 97.8% (95% CI 95–
100) and it was similar in children with and
without ERAP [97.3% (95% CI 94.1–100) versus
98.2% (95% CI 95.4–100), respectively; P = 0.38].
No child had early treatment failure (ETF). Late
parasitological failure (LPF) occurred in 13 children
(8 of 205 children versus 5 of 211 children in those
with and without ERAP, respectively). There was no
significant difference in the proportions of children
with late parasitological failure in the two groups
(P = 0.37). Overall parasite positivity on day 3 was 3
of 416 and it similar in children with and without
ERAP (2 of 205 versus 1 of 211, respectively, P =
0.62). Overall, mean fever clearance time was 1.1
day (95% CI 1.06–1.1, n = 295). Fever clearance was
similar in children with or without ERAP [1.1 day
(95% CI 1–1.2, n = 154) versus 1.1 day (95% CI 1–1.1,
































Fig. 1 Frequency and time distribution of children with early rising
asexual parasitaemia following artemisinin-based
combination treatments
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Table 3 Risk factors for early rising asexual parasitaemia in malarious children following artemisinin-based combination treatments
Variable Total no. No. with early rising asexual parasitaemia OR (95% CI) P value AOR (95% CI) P value
Gender
Female 209 103 1
Male 207 102 1.0 (0.7–1.5) 1.0 - -
Age (years)
≥ 5 332 169 1
< 5 84 36 0.8 (0.4–1.2) 0.19 - -
Duration of illness (days)
≤ 2 days 129 61 1
> 2 days 226 117 1.2 (0.8–1.8) 0.42 - -
Enrolment body temperature
≤ 38 °C 230 123 1
> 38 °C 186 82 1.5 (1.1–2.2) 0.06 - -
Fever on day 1
Absent 383 187 1
Present 30 16 1.2 (0.6–2.5) 0.63 - -
Haematocrit at presentation (day 0)
≥ 30% 320 156 1
< 30% 96 49 1.1 (0.7–1.7) 0.69 - -
Haematocrit on day1
≥ 30% 277 110 1
< 30% 121 66 1.5 (0.9–2.2) 0.09 - -
FIH
> 0.05 67 29 1
≤ 0.05 113 58 0.7 (0.4–1.3) 0.37 - -
Parasitaemia (μL−1)
≥ 100,000 125 40 1 1
< 100,000 291 165 2.8 (1.8–4.3) <0.0001 3.3 (2.1–5.3) <0.0001
Parasitaemia on day 1
Absent 325 144 1 1
Present 91 61 2.6 (1.6–4.2) <0.0001 3.8 (1.6–8.9) 0.002
PRRD1
≥ 104 302 134 1 1
< 104 114 71 2.1 (1.3–3.2) 0.001 0.9 (0.4–1.7) 0.52
PRRD2
≥ 104 378 187 1
< 104 38 18 0.9 (0.5–1.8) 0.8 - -
Fever clearance time
≤ 1 day 269 140 1
> 1 day 26 14 1.2 (0.5–2.7) 0.63 - -
Season of enrolment
Dry 97 44 1
Wet 319 161 1.2 (0.8–1.9) 0.38 - -
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(d).Parasite reduction ratio
Parasite reduction ratio 1 and 2 days after treatment
began was significantly higher in children without
compared with those with ERAP [2.8 × 104 (7.8 ×
100–1.1 × 106) versus 6.2 × 103 (5.6 × 10−1–5.4 × 105),
respectively, P < 0.0001 and 5.7 × 104 (1.6 × 101–1.1 ×
106) versus 4.6 × 103 (3.5 × 101–5.4 × 105),
respectively, P < 0.005]. In children with ERAP,
parasite reduction ratio 1 day after treatment
began was significantly lower in dihydroartemisinin-
piperaquine-treated children compared with
artesunate-amodiaquine- or artemether-
lumefantrine-treated children [1.6 × 103 (5.6 × 10−1–
1.2 × 105) versus 1.3 × 104 (2.8 × 100–4.7 × 105)
versus [3.7 × 104 (8.0 × 10−1–5.4 × 105), respectively,
P = 0.01]. However, parasite reduction ratio 2 days
after treatment began was similar in all 3 treatment
groups [4.8 × 104 (1.4 × 102–4.7 × 105) versus 5.4 ×
104 (1.8 × 103–5.4 × 105) versus [4.6 × 104
(3.5 × 101–4.2 × 105), respectively, P = 0.09]. Post hoc
comparison showed that parasite reduction ratio
2 days after treatment began was significantly higher
in artemether-lumefantrine-treated children com-
pared with dihydroartemisinin-piperaquine-treated
children (P = 0.03).
Kinetics of release of asexual parasites in children with ERAP
Data for evaluation of estimates of lag time, half-time and
the corresponding release rate constant were available in
all 205 children with ERAP. Figure 3 is a semi-logarithmic
plot of parasitaemia versus time by the method of resid-
uals in all 205 children with ERAP.
(a). Lag time: Overall, mean lag time was 0.2 h
(95% CI 0.2-0.3, range 0.02-0.9) and it was similar
with all 3 treatments: [0.2 h (95% CI 0.2–0.3, range
0.02–0.9, n = 107) versus 0.2 h (95% CI 0.2–0.3,
range 0.02–0.8, n = 64) versus 0.2 h (95% CI 0.2–0.3,
range 0.02–0.7, n = 34), respectively for AA, AL,
and DHP, P = 1.0].
Table 3 Risk factors for early rising asexual parasitaemia in malarious children following artemisinin-based combination treatments
(Continued)
Year of enrolment
≤ 2010 254 119 1
> 2010 162 86 1.3 (0.9–1.9) 0.21 - -
Treatment
Artesunate-amodiaquine 240 107 1
Artemether-lumefantrine 120 64 1.4 (0.9–2.2) 0.12 - -
Dihydroartemisinin-piperaquine 56 34 1.9 (1.1–3.5) 0.03
OR odd ratio, AOR adjusted odd ratio, CI confidence interval, FIH fall in haematocrit per 1000 asexual parasite cleared from peripheral, PRRD1 parasite reduction
ratio 1 day after treatment began, PRRD2 parasite reduction ratio 2 days after treatment began


























Fig. 2 Time-course of parasitaemia in malarious children with early rising asexual parasitaemia (red line), without early rising asexual
parasitaemia (blue line), and in all children (black line) following treatment with artesunate-amodiaquine, artemether-lumefantrine
or dihydroartemisinin-piperaquine
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(b).Half time: Overall, mean half-time of release of para-
sites into peripheral circulation was 1 h (95% CI 0.9–
1.1, range 0.1–4.9) and it was similar with all 3 treat-
ments: [1 h (95% CI 0.9–1.1, range 0.1–4.9, n = 107)
versus 1.2 h (95% CI 0.9–1.4, range 0.3–4.4, n = 64)
versus 1 h (95% CI 0.8–1.2, range 0.5–3.6, n = 34),
respectively for AA, AL, and DHP, P = 0.34].
(c). Rate constant of release: Overall, mean rate constant
for release of parasites into peripheral circulation
was 0.9 h−1 (95% CI 0.8–1, range 0.1–5.6) and it
was similar with all 3 treatments: [0.9 h−1 (95% CI
0.8–1.1, range 0.1–5.6, n = 107) versus 0.8 h−1
(95% CI 0.7–0.9, range 0.2–2.4, n = 64) versus
0.9 h−1 (95% CI 0.7–0.9, range 0.2–1.5, n = 34),
respectively for AA, AL, and DHP, P = 0.45].
(d). Factors influencing kinetics of the release of asexual
parasitaemia during early rising asexual parasitaemia:
Table 4 shows the clinical and parasitological
parameters that can influence the kinetics of release
of asexual parasitaemia in children with early rising
asexual parasitaemia. Of these parameters, only the
parasite clearance time significantly affected both the
lag time and the half-time of release of asexual
parasitaemia. With respect to the influence of parasite
clearance, there is a reciprocal relationship between
lag time and half-time of release if parasite clearance
time was ≤ 1 day.
Kinetics of the disposition of parasitaemia in children
with or without early rising asexual parasitaemia
Overall, geometric mean AUC from initiation of treat-
ment to clearance of parasitaemia in all children was
5.4 × 105 μL−1.h (95%CI 9.0 × 105–1.1 × 106, range 2.7 ×
103–1.1 × 107). Geometric mean AUCs at 0–4, 0–8, 0–
24 and 0–48 h after first dose were significantly higher
in children with early rising asexual parasitaemia com-
pared with children without early rising asexual parasit-
aemia (Table 5, Fig. 3). Overall, declines from peak
parasitaemias were monoexponential in children with
or without ERAP (Fig. 4). Overall estimated half-time
was 1.2 h (95% CI 1.1–1.2). Mean estimated half-times
were similar in children with and without ERAP [1.2 h
(95% CI 1.1–1.3) versus 1.2 h (95% CI 1.1–1.3), respect-
ively; P = 0.6] and in all treatment groups [1.2 h (95%
CI 1.1–1.2, n = 240) versus 1.2 h (95% CI 1.1–1.2, n =
120) versus 1.3 (95% CI 1.1–1.4, n = 56), P = 0.61] in
artesunate-amodiaquine-, artemether-lumefantrine- and
dihydroartemisinin-piperaquine-treated children, re-
spectively. Mean estimated half-times were also similar in
anaemic and non-anaemic children [1.2 h (95% CI 1.1–1.3,
n = 96) versus 1.2 h (95% CI 1.1–1.2, n = 320), respectively;
P = 0.49, Fig. 4]. In children with ERAP, mean estimated
half-times were similar with all 3 treatments [1.2 h
(95% CI 1.1–1.2, n = 107) versus 1.2 h (95% CI 1.1–
1.3, n = 64) versus 1.3 (95% CI 1.1–1.4, n = 34); P = 0.44]
Fig. 3 Estimates of lag time, half-time and rate constant of release of asexual parasitaemia by the method of residuals following a first dose of
artemisinin-based combination treatments of falciparum malaria (mean lag time, half-time and rate constant of release were 0.2 h, 1 h and
0.9 h−1, respectively)
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in artesunate-amodiaquine-, artemether-lumefantrine-
and dihydroartemisinin-piperaquine-treated children, re-
spectively. Similarly, in children without ERAP, estimated
half-times were similar with all 3 treatments [1.2 h (95%
CI 1.1–1.3, n = 133) versus 1.2 h (95% CI 1–1.2, n = 56)
versus 1.3 (95% CI 1.1–1.5, n = 22); P = 0.64] in
artesunate-amodiaquine-, artemether-lumefantrine- and
dihydroartemisinin-piperaquine-treated children, respect-
ively. The other pharmacokinetic parameters are summa-
rized in Table 5.
Stages of sexual and asexual parasitaemias in peripheral
blood
(a). Before treatment
Before treatment, gametocytaemia was detected in
peripheral blood of 12 children (3%): 6 children each
with or without early rising asexual parasitaemia.
Only mature gametocytes (Stages IV and V) were
detectable in peripheral blood. Ring forms of varying
stages were found in the peripheral blood of all
children. Late sequestering trophozoites and schizonts
were not found in peripheral blood of any child.
(b).Following first dose of ACTs
In the first 8 h following treatment, in children
without ERAP, different stages of ring forms were
found in peripheral blood of all children but
schizonts were found in peripheral blood of 1 child.
However, young gametocytes were not found in
peripheral blood. In children who subsequently
developed ERAP, different stages of ring forms were
found in peripheral blood of all children. However,
schizonts were found in peripheral blood films of 4
children and young gametocytes in peripheral blood
films of another 8 children (Fig. 5). After 2 weeks
following treatment, gametocytes were not found
in peripheral blood of any child.
Molecular genotyping
Table 6 shows the features of the 170 children (85 pairs)
with and without ERAP who were matched for clinical
and parasitological parameters at presentation. Asexual
parasitaemia was significantly higher in children with
ERAP compared to those without from 1 to 8 h after ini-
tiation of treatment (P ≤ 0.02 at all times, Table 6). How-
ever, parasite clearance time determined by microscopy
was similar in children with and without ERAP.
(a). Parasite DNA clones before and after first dose of
artemisinin-based combination treatments
Before treatment, of the 12 children with ERAP, 10
children had 1 clone infection and 1 each had 2
and 3 clone infections. In children without ERAP,
8 children had 1 clone infection and 4 had 2 clone
infections. Following first dose of ACTs in children
with ERAP, clone number increased in 4 children
(from 1 to 2 clones in 2 children, 1 to 5 clones in
1 child and 2 to 3 clones in 1 child). In children
without ERAP, clone numbers remained unchanged
in 11 of 12 children. However, clone number
reduced in 1 child from 2 to 1 at 4 h after first
dose of ACT. The time course of changes in
Table 4 Factors influencing the kinetics of release of asexual parasites in children with early rising asexual parasitaemia
Variables Lag time [Mean (95% CI)] (h) P value t½rls [Mean (95% CI)] (h) P value
Age <5 years (n = 36) v 0.3 (0.2–0.3) v 0.17 1 (0.7–1.2) v 0.42
≥5 years (n = 169) 0.2 (0.18–0.2) 1 (0.9–1.1)
Gender Male (n = 116) v 0.2 (0.17–0.2) v 0.21 1.1 (1–1.3) v 0.02
Female (n = 89) 0.2 (0.2–0.3) 0.9 (0.8–1)
Duration of illness ≤2 days (n = 61) v 0.2 (0.2–0.3) v 0.38 0.9 (0.8–1) v 0.02
>2 days (n = 117) 0.2 (0.2–0.3) 1.1 (0.9–1.2)
Enrolment parasitaemia ≤100000 μL−1 (n = 40) v 0.2 (0.1–0.3) v 0.43 1 (0.8–1.3) v 0.98
>100000 μL−1 (n = 165) 0.2 (0.2–0.3) 1 (0.9–1.1)
Enrolment temperature ≤37.4 °C (n = 51) v 0.3 (0.2–0.3) v 0.21 1 (0.7–1.2) v 0.4
>37.4 °C (n = 154) 0.2 (0.18–0.2) 1 (0.9–1.1)
Haematocrit <30% (n = 49) v 0.2 (0.2–0.3) v 0.54 1.1 (0.9–1.3) v 0.22
≥30% (n = 156) 0.2 (0.2–0.3) 1 (0.9–1.1)
Fever clearance time ≤1 days (n = 140) v 0.2 (0.2–0.3) v 0.33 1 (0.9–1.1) v 0.43
>1 days (n = 14) 0.2 (0.1–0.2) 0.9 (0.7–1.1)
Parasite clearance time ≤1 days (n = 144) v 0.25 (0.21–0.28) v 0.01 0.8 (0.7 – 0.8) v <0.0001
>1 days (n = 61) 0.18 (0.14–0.21) 1.6 (1.4–1.8)
t½rls half-time of release of asexual parasitaemia into peripheral blood, v versus
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parasite DNA clones before and following
artemisinin-based combination treatments are
shown in Fig. 6.
(b). Time to clearance of parasite DNA clones following
treatment
Parasite DNA clone clearance time was significantly
longer in children with compared to those without
early rising asexual parasitaemia [54 h (95% CI
44.5–63.5) versus 36 h (95% CI 28–43.9),
respectively; P = 0.004, see Fig. 6 Panels a and b].
(c). Relationship between time-course of parasitaemia
and changes in intensity of parasite DNA bands
In general, irrespective of clone number at
enrolment, DNA band intensity did not change in
the first 6–8 h in children without ERAP. In
children with ERAP, band intensities increased
within 1–4 h following initiation of treatment and
there was a significant correlation between time of
maximum parasitaemia and time of maximal
parasite DNA intensity (r = 0.62, P = 0.03). Figure 7
shows the relationship between parasite DNA band
intensity, time course of parasitaemia, and parasite
lag time, half-time and rate constant of release
of parasitaemia in a child with ERAP and the
corresponding pair without ERAP.
(d). Area under curve (AUC) of number of DNA clones
versus time
Area under curve of DNA clone number from
time of commencement of treatment till clearance
was significantly higher in children with ERAP
compared to those without ERAP [62.2 no.h
(95% CI 36.5–87.8) versus 28.8 no.h (95% CI
21.5–36), P = 0.02) [Fig. 6]. Figure 8 shows increase
in DNA clone number, area under curve of number
Table 5 Parameters for disposition of asexual parasitaemia in children with or without early rising asexual parasitaemia following
artemisinin-based combination treatments
Parameters Early rising asexual parasitaemia P value
Yes (n = 205) No (n = 211) All (n = 416)
Cmaxpd (μL
−1)
Geometric mean 91,502 61,639 74,887 0.01
Range 3,465-838,500 1,800-1,096,636 1,800-1,096,636
Tmaxpd (h)
Mean 2.6 0.2 1.4 <0.0001
95% CI 2.3–2.9 0.1–0.3 1.2–1.6
AUCpd (μL−1.h) <0.0001
0-4 h (Geometric mean) 2.6 × 105 1.5 × 105 2.0 × 105
Range 1.0 × 104–3.1 × 106 1.6 × 103–2.2 × 106 1.6 × 103–3.1 × 106
0–8 h (Geometric mean) 5.3 × 105 2.7 × 105 3.9 × 105 0.001
Range 2.0 × 104–5.9 × 106 2.2 × 103–2.4 × 106 2.2 × 103–5.9 × 106
0–24 h (Geometric mean) 7.8 × 105 3.6 × 105 5.3 × 105 <0.0001
Range 2.9 × 104–1.1 × 107 2.7 × 103–4.1 × 106 2.7 × 103–1.1 × 107
0–48 h (Geometric mean) 7.9 × 105 3.7 × 105 5.4 × 105 <0.0001
Range 2.9 × 104–1.1 × 107 2.7 × 103–4.5 × 106 2.7 × 103–1.1 × 107
0–∞ (Geometric mean) 8.0 × 105 3.7 × 105 5.4 × 105 <0.0001
Range 2.9 × 104–1.1 × 107 2.7 × 103–4.5 × 106 2.7 × 103–1.1 × 107
CLBpd (Lh
−1)
Mean 0.1 0.4 0.3 <0.0001
95% CI 0.1–0.2 0.3–0.4 0.2–0.3
Elimination half-time (h)
Mean 1.2 1.2 1.2 0.6
95% CI 1.1–1.3 1.1–1.2 1.1–1.2
Elimination rate constant (h−1)
Mean 0.6 0.6 0.6 0.9
95% CI 0.6–0.7 0.6–0.7 0.6–0.7
h hour, Cmaxpd maximum asexual parasite density (concentration), Tmaxpd time to reach maximum asexual parasite density (concentration), CLBpd volume of blood
cleared of parasitaemia per unit of time, AUCpd area under curve of plot of parasite density (parasitaemia) versus time
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of clone and the disposition of DNA clone in a
child with ERAP and the corresponding pair
without ERAP. Declines in clone number were
monoexponential with similar half-times in the
matched pairs of children with and without ERAP
(3.4 h (95% CI 3.1–3.7) v 3.1 h (95% CI 2.7–3.4),
P = 0.15, Figs. 6 and 8)
Relationship between early rising asexual parasitaemia
and late-appearing anaemia
In a univariate analysis, a haematocrit <30% was not as-
sociated with early rising asexual parasitaemia (Table 3).
The proportions of children with or without early rising
parasitaemia who subsequently developed late-appearing
anaemia were similar: 28 of 205 (14%) versus 24 of 211
(11%). P =0.48. Similarly, the proportions of children
with anaemia at presentation and who subsequently
developed late-appearing anaemia in children with or
without early rising asexual parasitaemia were also simi-
lar: 9 of 49 (18%) versus 8 of 47 (17%). P = 0.86. When
matched for age, gender, same day presentation and same
treatment, the proportion of children with or without
early rising parasitaemia who developed late-appearing an-
aemia were also similar 12 of 85 (14%) versus 9 of 85
(11%). P = 0.64 (Table 6).
Reported adverse events
Eighty two of 205 (40%) children and 66 of 211 (31%)
children with and without early rising asexual parasit-
aemia, respectively, reported at least 1 adverse event in
the first week of starting treatment. There was no sig-
nificant difference in the proportions reporting adverse
events in the 2 groups (P = 0.08). In children with early
rising asexual parasitaemia, 23 (11%), 15 (7%), 11 (5%), 2
(1%), 15 (7%), 15 (7%), 9 (4%), 11 (5%) and 3 (1%) chil-
dren reported abdominal pain, fever, vomiting, weakness,
headache, cough, anorexia, running nose and diarrhoea,
respectively. In children without early rising asexual
parasitaemia, 17 (8%), 13 (6%), 5 (2%), 1 (0.5%), 12 (6%),
16 (8%), 5 (2%), 7 (3%) and 4 (2%) children reported








































Fig. 4 Semilogarithmic plots of asexual parasitaemia versus time (a) in all children (black line), children with (green line) and without (blue line)
early rising asexual parasitaemia, and (b) in anaemic (blue line) and non-anaemic (green line) children treated with artesunate-amodiaquine,
artemether-lumefantrine or dihydroartemisinin-piperaquine
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abdominal pain, fever, vomiting, weakness, headache,
cough, anorexia, running nose and diarrhoea, respectively.
There was no significant difference in the proportions
reporting each of these adverse events in the children with
and those without early rising asexual parasitaemia.
Discussion
In this study, we described the clinical and parasito-
logical features, the risk factors for, the kinetics of the
release and of the disposition of asexual parasitaemia,
the parasite population changes, the molecular features
of and the relationship between early rising asexual
parasitaemia and late-appearing anaemia following
artemisinin-based combination treatments in a cohort
of children resident in an endemic area. Using a definition
of early rising asexual parasitaemia of ≥5% increase in
baseline (enrolment) parasitaemia occurring within the
first 8 h of initiating artemisinin-based combination
treatments showed half of the children had significant in-
creases in baseline parasitaemia that peaked 2.5 h after
first dose. Time to peak parasitaemia was significantly
longer and the peak parasitaemia significantly higher in
children with compared to those without early rising asexual
parasitaemia.
Of the three factors associated with early rising asexual
parasitaemia (Table 3), enrolment parasitaemia <100,000/uL
and parasitaemia 1 day post-treatment initiation were inde-
pendent predictors of early rising asexual parasitaemia.
Taken together, these factors would suggest: (i). In these
children, a relatively ‘low’ baseline peripheral asexual parasit-
aemia may indicate a relatively ‘large’ parasite biomass in
deep tissues that was, following treatment, quickly mobilized
after a first dose; (ii). Mobilization resulted in significantly
higher peak asexual parasitaemia compared to that in
children without early rising asexual parasitaemia in the first
4–8 h post-treatment initiation (Fig. 2); (iii). The higher
peripheral parasitaemia was then cleared relatively slowly.
The last supports reports of slower clearance of high
parasitaemias compared to lower parasitaemias by
artemisinin-like drugs [33, 36]. The significant association of
dihydroartemisinin-piperaquine compared with artemether-
lumefantrine treatment with early rising asexual parasit-
aemia may in part be due to the lag time required for
converting artemether to its metabolite, dihydroartemisinin.
The significantly slower clearance of parasitaemia and lower
parasite reduction ratio one day after treatment began in
children treated with dihydroartemisinin-piperaquine may
also be contributory to its significant association with




Fig. 5 Light micrograph of Plasmodium falciparum in the first 8 h after a first dose of artemisinin-based combination treatments. Panel a shows
female and male gametocytes, Panel b shows immature gametocytes, and Panel c shows schizonts found in peripheral blood of children with
early rising asexual parasitaemia
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The rapid release of asexual parasites into peripheral
blood by 12 min of initiating treatment with all 3 arte-
misinins coupled with the short release half-time indicate
release kinetics are rapid first order processes attributable
to first dose of artemisinins. Of the factors that may affect
release kinetics, it would appear parasite clearance time,
which showed a reciprocal relationship between lag time
and half-time of release, is the most intriguing. The
Table 6 Features of children with or without early rising asexual parasitaemia matched for gender, enrolment parasitaemia,
treatment and same day presentation who were treated with artesunate-amodiaquine, artemether-lumefantrine or
dihydroartemisinin-piperaquine
Early rising asexual parasitaemia P value
Yes (n = 85) No (n = 85) ALL (n = 170)
Temperature (°C)
Mean 38.3 38 38.1 0.07
95% CI 38.1–38.6 37.7–38.3 37.9–38.3
Fever on day 1 9 5 14 0.27
Fever clearance time (day)
Mean 1.1 (n = 66) 1.1 (n = 52) 1.1 (n = 118) 0.59
95% CI 1–1.2 1–1.2 1–1.1
Geometric mean parasitaemia (μL−1)
At enrolment (0 h) 61,165 59,853 60,505 0.96
Range 2,928–536,912 2,000–500,000 2,000–536,912
1 h 74,268 39,865 55,059 0.001
Range 2, 136–763,500 790–314,030 790–763,500
2 h 71,410 30,689 46567 <0.0001
Range 2,976–838,500 284–313,980 284–838,500
4 h 57,650 24,043 38,394 <0.0001
Range 210–785,610 339–253,304 210–785,610
6 h 33,950 9,604 18,312 0.02
Range 980–531,000 321–133,400 321–531,000
8 h 37,017 8,052 16,919 0.002
Range 656–616,119 106–266,400 106–616,119
Parasite positivity
On day 1 [%] 18 [21] 13 [15] 31 [20] 0.32
On day 3 [%] 1 [1] 1 [1] 2 [1] 1.0
PRRD1
Geometric mean 1.6 × 104 2.7 × 104 2.1 × 104 0.68
Range 6.5 × 10−1–5.4 × 105 9.8 × 100–5.0 × 105 6.5 × 10−1–5.4 × 105
PRRD2
Geometric mean 6.1 × 104 5.6 × 104 5.9 × 104 0.78
Range 2.9 × 103–5.4 × 105 6.0 × 102–5.0 × 105 6.0 × 102–5.4 × 105
Parasite clearance time (day)
Mean 29.6 28.5 29.1 0.53
95% CI 27–32.3 26.1–30.9 27.3–30.9
Anaemia on day 1 29 22 51 0.22
Anaemia recovery time (day)
Mean 13.2 (n = 21) 10.6 (n = 24) 11.6 (n = 44) 0.25
95% CI 10.5–15.9 6.8–14.4 9.2–13.9
No. with late-appearing anaemia 12 9 21 0.64
H hour, PRRD1 parasite reduction ratio 1 day after treatment began, PRRD2 parasite reduction ratio 2 days after treatment began, CI confidence interval
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reason(s) is (are) unclear. However, anaemia did not affect
release kinetics indicating release kinetics are not impaired
in anaemic children. Evidently, there is no artemisinin
resistance in P. falciparum in the study area ([27, 33] and
as shown in the present study) and is unclear if the ‘first
dose phenomenon’ will be modified by development of
artemisinin resistance should this occur in the future.
Pre-treatment gametocyte carriage was low (3%) in this
cohort of children. Nonetheless, young gametocytes were
demonstrable after first dose only in few children with
early rising asexual parasitaemia. Theoretically, their
mobilization into peripheral circulation can be advanta-
geous in two ways: exposing them to higher drug concen-
trations and enhancing the gametocytocidal effects of the
first doses of artemisinins and their partner drugs, all of
which are gametocytocidal to young gametocytes [37, 38];
and preventing further development in bone marrow to
mature gametocytes which are not sensitive to killing
effects of the artemisinin-based combination treatments
evaluated. It has been shown that a male-biased sex ratio
is more infective to mosquitoes [19], and a selective alter-
ation of gametocyte sex ratios during early rising sexual
parasitaemia (ERSP) can produce a female biased sex ratio
[3, 39, 40], which is less likely to be infective to mosqui-
toes. However, gametocyte sex ratio changes were not
evaluated in the present study because gametocytaemia
was less than 10/μL, the lower threshold for estimating
sex ratio [39, 40] in patients with demonstrable peripheral
gametocytes. Demonstrable sequestering forms of asexual
parasites (late trophozoites and schizonts) in peripheral
blood also suggests mobilization from deep tissue to
peripheral blood.
















































































Fig. 6 Time-course of changes in parasite DNA clones in age-, gender-, parasitaemia- and treatment-matched children with [1] and without [2]
early rising asexual parasitaemia following artemisinin-based combination treatment. Panel a shows individual (black lines) and mean (red line) of
area under curves (AUC of clone number versus time) in children with ERAP. Panel b shows individual (black lines) and mean (red line) of area
under curves (AUC of clone number versus time) in children without ERAP. Panels c and d show semilog plots of mean clone number versus time
in children with and without ERAP, respectively. Declines from peak clone number were monoexponential (mean estimated half-times were 3.4 h
(95% CI 3.1–3.7) and 3.1 h (95% CI 2.7–3.4), respectively)
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Overall, as expected, the area under curve of asexual
parasitaemia versus time but not the terminal elimination
half-times of parasitaemia was significantly higher in chil-
dren with early rising asexual parasitaemia compared to
those without. The significantly higher area under curve
in the first 8–24 h post-treatment initiation indicates large
peripheral asexual parasite burden in children with
early rising asexual parasitaemia is largely due to a ‘first
0h    1h    2h   4h   6h   8h  24h






















































































0h    1h    2h   4h   6h   8h  24h
Patient ID - DP-014 (1) Patient ID - DP-019 (2) 
Fig. 7 Features of molecular, time course, and release kinetics of asexual parasitaemia in age-, pre-treatment parasitaemia- and same treatment-
matched malarious children with (1) and without (2) early rising asexual parasitaemia after first dose of dihydroartemisinin-piperaquine. Panel a
shows increase in parasite clones from one to two and maximum parasite DNA band intensity 2 h post-initiation of treatment followed by
decreasing intensity after 6 h. Parasite DNA clearance time was 48 h. Panel b shows stable number of clones (two in all) pre- and post-
initiation of treatment and no change in DNA band intensity in the first 6 h followed by decrease in intensity. Parasite DNA clearance time
was 24 h. Panel c shows peak parasitaemia at 2 h coincides with maximum DNA band intensity in Panel a. Panel d shows decreasing parasitaemia
parallels DNA band intensity in Panel b. Panel e shows release kinetics estimated by method of residuals (lag time, half-time, and rate constant of
0.2 h, 0.5 h and 1.5 h−1, respectively, and monoexponential terminal elimination half-time of 2.3 h. Panel f shows only monoexponential terminal
elimination half time of 1.7 h
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dose artemisinin phenomenon’. Also, as expected, in
age-and treatment-matched children with and without
early rising asexual parasitaemia, parasite clearance
determined by microscopy was rapid and similar in both
groups. However, parasite DNA clearance was significantly
longer in children with early rising asexual parasitaemia
indicating PCR is more sensitive than microscopy in detect-
ing low peripheral parasitaemia. Taken together, the signifi-
cantly higher area under curve and significantly slower
clearance of parasite DNA indicate significant retention, in
the peripheral blood, of asexual parasites that were likely
released from deep tissue sites into peripheral blood in
children with early rising asexual parasitaemia. Similarly,
the significantly higher area under curve of the plot of
number of clones versus time at 8 h or after initiation of
treatment indicates significant retention of parasite clones
in the peripheral blood of children with early rising asexual
parasitaemia. Thus, taken together, the significant magni-
tude and duration of parasitaemia and parasite clones in
peripheral blood during the early hours following initiation
of treatment are molecular features of first dose of artemisi-
nins and are not indicative of in vivo reduced artemisinin
susceptibility in this endemic area. The monoexponential
declines in clone number in children with or without early
rising asexual parasitaemia who had multiple clones at initi-
ation of treatment or following first dose indicate clone
elimination is a first order process (Fig. 7). Overall, the mo-
lecular features allow the development of the ‘concept of
clone retention’ (measured as area under curve) and ‘clone
elimination half-time’ (determined by a monoexponential
declines from peak clone number) following a first dose of
an artemisinin-like drugs.
A B0h 1h 2h 4h 8h 24h 48h 0h 1h 2h 4h 8h 24h 48h



















































































AUC0-8 = 31.5 no.h
AUC0-t = 143.5 no.h
Patient ID - DETV 020 (1) Patient ID – DETV 004 (2) 
AUC0-8 = 8 no.h
AUC0-t = 36 no.h
Fig. 8 Parasite DNA clone number, area under curve of number of DNA clones versus time, and elimination kinetics of parasite DNA clones in
age-, pre-treatment parasitaemia- and same treatment-matched malarious children with (1) and without (2) ERAP treated with artesunate-
amodiaquine. Panel a shows increase in parasite DNA clones from one to five 1 h post-initiation of treatment. Parasite DNA clearance time was
48 h. Panel b shows stable number of DNA clone (one at all times) pre- and post-initiation of treatment and no change in parasite DNA clone
number following treatment. Parasite DNA clearance time was 24 h. Panels c and d show area under curve of number of clones versus time in
children with and without ERAP, respectively. Panel e and f show monoexponential terminal elimination of DNA clones in children with and
without ERAP, respectively. Note: Declines in DNA clone numbers were monoexponential
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Overall, although a disadvantage of early rising
asexual parasitaemia is increasing circulating parasite
biomass, a distinct advantage of this first dose
phenomenon is a reduced likelihood of and lower se-
questering or sequestered parasite biomass. This, in
addition to relatively rapid clearance of parasitaemia,
should lead to reduced likelihood of progression of
non-severe to severe malaria in these children be-
cause severe malaria has been attributable to parasite
sequestration in vital organs [41, 42], or to release of,
and imbalance between pro-inflammatory and anti-
inflammatory cytokines by sequestered parasites in
deep tissue [43]. In this context, controlled studies
are required to evaluate the risks and consequences
of progression to severe malaria in children with un-
complicated malaria who subsequently develop or did
not develop early rising asexual parasitaemia following
initiation of artemisinin-based combination treatments.
Although early rising asexual parasitaemia has been
attributed to mobilization of parasites from deep tissues
[2, 3], it could also have resulted from large numbers of
schizonts bursting to release young ring forms into per-
ipheral circulation after first dose of artemisinins. Can
this also be an artemisinin effects? This is possible. The
broad stage effects of artemisinins from rings aged 6 h
and above [17], would act on these young rings in the first
8 h of the first dose. It is also possible that, acting by un-
known mechanism, artemisinin-like drugs are more likely
to cause more peripheral circulating rather than deep
tissue retention of asexual parasites in children with early
rising asexual parasitaemia. In this regard, studies are
urgently needed on the effects of artemisinins on binding of
asexual parasite-infected red blood cells to tissue proteins.
A postulate of the present study was increase
mobilization of asexual parasites from deep tissue into
peripheral circulation would increase the number of
infected red blood cells pitted by the spleen. This
process could lead to increase in number of once-
infected red blood cells in peripheral circulation. The
once-infected red blood cells may thereafter be destroyed
7–21 days later causing a relatively asymptomatic late-
appearing anaemia following artemisinin-based combin-
ation treatments in patients with early rising asexual
parasites compared with those without. This postulate
was not realised in children with early rising asexual
parasites compared with those without as evidenced by
similar frequency of late-appearing anaemia in children
with or without early rising asexual parasitaemia.
Additionally, anaemia had no effect on asexual parasite
release kinetics in children with early rising asexual para-
sitaemia. When compared with the recently described
features of late-appearing anaemia [7], there are significant
differences in risk factors for the two conditions. The
differences are particularly striking with respect to age,
presence of anaemia at enrolment or 1 day after
treatment began, parasite reduction ratios, and para-
site clearance times, which are diametrically opposite
in these two conditions associated with artemisinin-
based combination treatments (see reference [7]). Per-
haps the lack of association between early rising
asexual parasites and late-appearing anaemia is one of
the ‘beneficial effects’ of artemisinin-like drugs. Stud-
ies are now necessary to quantify once- infected red
blood cells in patients with or without early rising
asexual parasites following artemisinin-based combin-
ation treatments.
There is need to justify the definition of early rising
parasitaemia used in the present study. Firstly, a ≥5% in-
crease in parasitaemia from baseline in a relatively short
time frame is unlikely to be a random effect. Secondly,
in a manner similar to a two-way analysis of variance, it
is likely to represent a significant increase in parasit-
aemia from baseline in a short time frame that would
result in two populations of children: those with and
those without early rising asexual parasitaemia after a
first dose of artemisinins. Thirdly, the lag time of 12 min
after a first dose and ≥5% increase in baseline parasit-
aemia indicate it is a first dose artemisinin effect and it
is unlikely to be due to reduced sensitivity or resistance
in the parasites that are released into peripheral circula-
tion. Fourthly, with an estimated half-life of 1 h or less,
>99% of an administered first dose of oral artemisinin
would have been eliminated in 8 h lending credence to
this critical time frame, and attributing the response
most likely but not exclusively to artemisinin-like drug
action. Finally, the definition is not in agreement with in
vivo measures of artemisinin resistance measured as
parasite positivity rate 3 days after commencement of
treatment >3% in patients with pre-treatment parasit-
aemia <100,000/μL or >10% of patients with detectable
P. falciparum parasitaemia 72 h after initiation of direct
observed therapy [44, 45]. The similar frequency of
early rising asexual parasitaemia and non-early rising
asexual parasitaemia in the population of children
evaluated would suggest there is a possible genetic
basis for this ‘first dose phenomenon’. Whether the
genetic basis is host- or parasite-related is conjectural.
More studies are now needed to explore the basis of
this phenomenon.
There are limitations of the study. These include not
using a quantitative method (qPCR) to assess the amount
of DNA in patients samples during the various time
points, in samples obtained in children with or without
early rising asexual parasitaemia to justify the increased
intensity observed on PCR gels and not estimating once-
infected red blood cells in the postulate to establish the
relationship between early rising asexual parasitaemia and
late- appearing anaemia.
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Conclusion
In conclusion, early rising asexual parasitaemia is com-
mon, occurs rapidly as first order process and may be due
to mobilization of parasites from deep tissue following a
first dose ACTs of acute childhood falciparum malaria.
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